Six bryostatins were isolated from Japanese bryozoan by evaluating their binding to the C1B domain of protein kinase C (PKC). Structure-activity studies of bryostatins 4, 10, and 14 suggested that the ester group at C20 was not necessary for binding to and activating PKC. These bryostatins showed significant anti-tumorpromoting activity in induction tests with the EpsteinBarr virus early antigen.
Protein kinase C (PKC) isozymes play a crucial role in cellular signal transduction via second-messenger diacylglycerols. 1) Protein kinase C (PKC), one of the PKC isozymes, is involved in tumor suppression and apoptosis.
2,3) Bryostatin 1 (bryo-1, Fig. 1 ), which was isolated from the marine bryozoan, Bugula neritina, 4) showed strong anti-cancer and anti-tumor-promoting activity through PKC-dependent mechanisms. 5, 6) Bryo-1 has also attracted strong attention as a therapeutic lead against Alzheimer's disease and acquired immune deficiency syndrome. 7) Although 20 bryostatin homologues have been identified, 6, 8, 9) their limited availability from nature has hampered studies of their structureactivity relationships and molecular mechanisms of action. It is necessary to develop a convenient and reliable way to identify bryostatins and bryostatin-like compounds with high sensitivity and selectivity.
Bryo-1 binds to the cysteine-rich C1 domains of PKC isozymes (C1A and C1B) for their activation. 1) Since whole PKC isozymes are highly unstable and precious, our group has developed a synthetic C1 peptide library that binds to PKC activators with an affinity comparable to that of whole PKC isozymes. 10, 11) We screened in this present study for PKC ligands in marine organisms by evaluating their binding to a C1B peptide of PKC (-C1B) based on competition with the potent PKC activator, [ 3 H]phorbol 12,13-dibutyrate (PDBu, PerkinElmer Japan, Yokohama, Japan).
Among over 200 CHCl 3 /MeOH extracts of marine organisms (sponges, cyanobacteria, and bryozoan) collected by the OP-BIO Factory Co. (Okinawa), several extracts of B. neritina exhibited high affinity for -C1B. This bryozoan found in the Gulf of Imazu (Fukuoka, Japan) was harvested in the summer of 2010. Extraction of the animal (6 kg wet weight) was carried out twice with CHCl 3 /MeOH (1:1). The extract after evaporation was partitioned three times between EtOAc and water. The resulting EtOAc extract (26.5 g) was chromatographed on Wakogel C-200 (silica gel, Wako Pure Chemical Industries, Osaka, Japan), sequentially eluting with 100% CHCl 3 , 30% EtOAc in hexane, 100% EtOAc, and 100% MeOH, to give two active fractions from the 100% EtOAc and MeOH eluates. These were purified again on the same silica gel with i-PrOH- The FAB-MS data (Jeol JMS-600, m-nitrobenzyl alcohol as a matrix, except glycerol for bryo-8 and bryo-10) for the compounds isolated in this study are as follows: , optical rotation (P-2200, Jasco, Tokyo, Japan), and FAB-MS (Jeol JMS-600, Tokyo, Japan) for these bryostatins were identical to those previously reported. Although Kamano et al. have identified bryo-4, 5, 6, 8, 9, and 10 from the Japanese bryozoan in the Gulf of Aomori, Ohzuchi and Sagami, 15, 17, 18) bryo-14 and 19 were alternatively identified in this study. Bryo-1, the major component of the American bryozoan, 4) could not be found at all in this sample. These results suggest that the geographical difference of B. neritina could affect the variability of the types and amounts of bryostatin homologues.
Bryo-4, 5, 10, and 14 all had a pivaloyl group on the A-ring, but had different substituents at C20 of the C-ring (Fig. 1) . Little is known about the role of these substituents in the biological activities of bryostatins. Wender's group 19) have synthesized a simplified analogue of bryo-1 with several ester substituents at C20, and suggested a correlation between the number of carbons on the C20 ester and the affinity for a mixture of rat PKC isozymes. However, the role of the ester and hydroxyl groups at C20 in the various biological activities of bryostatins has remained elusive. We therefore examined the biological activities of bryo-4, -10, and -14. The biological evaluation of bryo-5 was almost impossible because of its small amount.
Since the unique biological properties of bryo-1 are considered to be correlated with the activation of PKC, 20) we evaluated the ability to bind to and activate PKC by using our PKC C1 peptides 10, 11) and human recombinant PKC (Pan Vera LLC, Madison, USA Table 1 shows that the K i values of bryo-4 and 10 for whole PKC were almost equal to each other and comparable to those of -C1B. Both compounds bound significantly to -C1A as reported for bryo-1 (K i for -C1A and -C1B, 5.3 and 0.60 nM) unlike tumor promoters. 22) This suggests that the structural difference in the C20 side chain between bryo-1 and bryo-4 hardly changed the ability to bind to PKC C1 peptides. In contrast, the K i values of bryo-14 for whole PKC and its C1 peptides were about 8 times larger than those of bryo-4 and 10, possibly due to the hydroxyl group at C20. These results indicate that the hydrophobicity at C20 slightly influenced the binding to PKC, but that the C20 ester group did not increase the binding ability. This conclusion is in contrast with that obtained when using the C20 esters of Wender's simplified analogue of bryo-1; 19 ) the hydrophobic C20 ester was necessary to potently bind to rat PKC isozymes in Wender's analogues.
To evaluate the ability of these bryostatins to activate PKC, the phosphorylation levels were measured by using a fluorescence-labeled peptide substrate (PepTag Ò non-radioactive protein kinase assay; Promega, Tokyo, Japan) according to the manufacturer's instructions ( Fig. 2A) . After the reaction had been stopped by heating at 95 C for 10 min, the samples were loaded on to 0.8% agarose gel (Nippon Gene, Toyama, Japan) which was then quantified by densitometry software (NIH ImageJ, Bethesda, MD, USA). Bryo-4 and -10 both activated PKC even at 1:0 Â 10 À8 M, comparable to 12-O-tetradecanoylphorbol 13-acetate (TPA) as a positive control, while bryo-14 showed slightly weaker activation. These activation profiles are in good agreement with the results of the binding assay (Table 1) .
Anti-tumor-promoting activity is characteristic of bryo-1 23) while most PKC activators in nature are tumor promoters. The anti-tumor-promoting activity was evaluated in vitro, based on the inhibitory activity of the Epstein-Barr virus early antigen (EBV-EA) induced by TPA. 24, 25) EBV is activated by treating with a tumor promoter like TPA to generate EA which can then be detected by an indirect immunofluorescence technique. Figure 2B shows that TPA generated about 30% of EA-positive cells at 3:16 Â 10 À8 M. In contrast, bryo-4, -10, and -14 showed almost no induction (1:0 Â 10 À7 M), even at 1:0 Â 10 À6 M (data not shown), and significantly attenuated the induction by TPA (3:16 Â 10 À8 M). Quite similar results have been reported for bryo-1. 23) These results suggest that bryo-4, -10, and -14 had little tumorpromoting activity and that the inhibitory activity of EBV-EA was not related to the structure at C20. This was consistent with the finding that 20-epi-bryo-7, with an acetyloxy group at C20, exhibited significant biological activity in antiproliferative assays against several cancer cell lines. 26) These data do not reflect well the difference in the binding affinity to PKC, possibly because these data were measured at a higher concentration (1:0 Â 10 À7 M) when compared with the K i values for PKC (1:0 Â 10 À9 M).
In summary, we screened and identified six bryostatins from the Japanese bryozoan by using a [
3 H]PDBu binding assay with the PKC-C1B peptide developed by us. Structure-activity studies on bryo-4, -10, and -14 clearly indicated that the C20 ester was not necessary for binding to and activating PKC, nor for the anti-tumorpromoting activity of bryostatins. As Wender has suggested, 19, 27) this means that one can utilize this position to introduce a photoaffinity label or a linker to identify new targets other than PKC isozymes. Since bryostatins are not tumor promoters, conventional assays for PKC ligands such as EBV-EA induction are not applicable. The assay presented in this paper would be useful for finding new PKC ligands with antagonistic activities like bryostatins.
